<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0802221696
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        DUETACT 30/4 mg tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIOGLITAZONE,GLIMEPIRIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        30,4
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        125.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TAKEDA GMBH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TAKEDA GMBH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 441]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jazeera Pharmaceutical Industries (JPI)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BD06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Duetact contains pioglitazone and glimepiride which are anti-diabetic medicines, used to control blood sugar level.</p><p>It is used in adults when metformin is not suitable to treat type 2 (non-insulin dependent) diabetes mellitus. This type 2 diabetes usually develops in adulthood where the body either does not produce enough insulin (a hormone that controls blood sugar levels), or cannot effectively use the insulin it produces.</p><p>Duetact helps control the level of sugar in your blood when you have type 2 diabetes by increasing the amount of insulin available and helping your body make better use of it. Your doctor will check whether Duetact is working 3 to 6 months after you start taking it.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Duetact</strong></p><ul><li>If you are allergic to pioglitazone, glimepiride, other sulphonylureas or sulphonamides, or any of the other ingredients of this medicine (listed in section 6)</li><li>If you have heart failure or have had heart failure in the past</li><li>If you have liver disease</li><li>If you have diabetic ketoacidosis (a complication of diabetes with rapid weight loss, nausea or vomiting)</li><li>If you have severe problems with your kidneys</li><li>If you have or have ever had bladder cancer</li><li>If you have blood in your urine that your doctor has not checked</li><li>If you have insulin dependent diabetes (Type 1)</li><li>If you are in a diabetic coma</li><li>If you are pregnant</li><li>If you are breast-feeding</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before you start to take Duetact (see also section 4).</p><ul><li>If you have a problem with your heart. Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin together experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema)</li><li>If you retain water (fluid retention) or have heart failure problems in particular if you are over 75 years old. If you take anti-inflammatory medicines which can also cause fluid retention and swelling, you must also tell your doctor</li><li>If you have a special type of diabetic eye disease called macular oedema (swelling of the back of the eye)</li><li>If you have a problem with your liver. Before you start taking Duetact you will have a blood sample taken to check your liver function. This check should be repeated at intervals. Inform your doctor as soon as possible if you develop symptoms suggesting a problem with your liver (like feeling sick without explanations, vomiting, abdominal pain, tiredness, loss of appetite and/or dark urine) as your liver function should be checked.</li><li>If you have cysts on your ovaries (polycystic ovary syndrome). There may be an increased possibility of becoming pregnant because you may ovulate again when you take Duetact. If this applies to you, use appropriate contraception to avoid the possibility of an unplanned pregnancy</li><li>If you are already taking other medicines for the treatment of diabetes</li><li>If you have problems with your enzyme called Glucose-6-phosphodehydrogenase since it can decrease your red cells</li></ul><p>You may also experience a reduction in blood count (anaemia). Your doctor may take blood tests to monitor your blood cell levels and liver function.</p><p><em>Hypoglycaemia</em><br />When you take Duetact, your blood sugar could fall below the normal level. It is important to know what symptoms to expect when low blood sugar (hypoglycaemia) occurs. Ask your doctor or pharmacist for more information if you are not sure how to recognise this. The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea. Tell your doctor if you notice such symptoms. The level of sugar in your blood or urine should be checked regularly.</p><p><em>Broken bones</em><br />A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. Your doctor will take this into account when treating your diabetes.&nbsp;</p><p><strong>Children and adolescents</strong><br />Use in children and adolescents under 18 years is not recommended.</p><p><strong>Other medicines and Duetact</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some medicines can weaken or strengthen the effect of Duetact on the level of sugar in your blood.</p><p>The following medicines can increase the blood sugar lowering effect of Duetact. This can lead to a risk of hypoglycaemia (low blood sugar):</p><ul><li>Gemfibrozil and fibrates (to lower high cholesterol level)</li><li>Insulin, metformin or other medicines to treat diabetes mellitus</li><li>Phenylbutazone, azapropazone, oxyphenbutazone, aspirin-like medicines (to treat pain and inflammation)</li><li>Long acting sulphonamides, tetracyclines, chloramphenicol, fluconazole, miconazole, quinolones, clarithromycin (to treat bacterial or fungal infections)</li><li>Anabolic steroids (supporting muscle build up) or male sex hormone replacement therapy</li><li>Fluoxetine, MAO-inhibitors (to treat depression)</li><li>ACE inhibitors, sympatholytics, disopyramide, pentoxifylline, coumarin derivatives such as warfarin (to treat heart or blood problems)</li><li>Allopurinol, probenecid, sulfinpyrazone (to treat gout)</li><li>Cyclophosphamide, ifosfamide, trofosfamide (to treat cancer)</li><li>Fenfluramine (to reduce weight)</li><li>Tritoqualine (to treat allergies)</li></ul><p>The following medicines may decrease the blood sugar lowering effect of Duetact. This can lead to a risk of hyperglycaemia (high blood sugar level):</p><ul><li>Oestrogens, progestogens (female sex hormones)</li><li>Thiazide diuretics and saluretics also called water tablets (to treat high blood pressure)</li><li>Levothyroxine (to stimulate the thyroid gland)</li><li>Glucocorticoids (to treat allergies and inflammation)</li><li>Chlorpromazine and other phenothiazine derivatives (to treat severe mental disorders)</li><li>Adrenaline and sympathicomimetics (to increase heart beat, to treat asthma or nasal congestion, coughs and colds or used in life-threatening emergencies)</li><li>Nicotinic acid (to treat high cholesterol level)</li><li>Long-term use of laxatives (to treat constipation)</li><li>Phenytoin (to treat fits)</li><li>Barbiturates (to treat nervousness and sleep problems)</li><li>Azetazolamide (to treat increased pressure in the eye also called glaucoma)</li><li>Diazoxide (to treat high blood pressure or low blood sugar)</li><li>Rifampicin (to treat infections, tuberculosis)</li><li>Glucagon (to treat severe low blood sugar levels)</li></ul><p>The following medicines can increase or decrease the blood sugar lowering effect of Duetact:</p><ul><li>H2 antagonists (to treat stomach ulcers)</li><li>Beta-blockers, clonidine, guanethidine and reserpine (to treat high blood pressure or heart failure). These can also hide the signs of hypoglycaemia, so special care is needed when taking these medicines</li></ul><p>Duetact may either increase or weaken the effects of the following medicines:</p><ul><li>Coumarin derivatives such as warfarin (to slow down or stop blood clotting)</li></ul><p>Tell your doctor or pharmacist if you are taking any of these. Your blood sugar will be checked, and your dose of Duetact may need to be changed.</p><p><strong>Duetact with food and drink and alcohol</strong><br />Avoid alcohol while taking Duetact since alcohol may increase or decrease the blood sugar lowering action of Duetact in an unpredictable way.</p><p><strong>Pregnancy and breast-feeding</strong><br />Do not use Duetact if you are pregnant. You must tell your doctor if you are, you think you may be pregnant or are planning to have a baby. Your doctor will advise you to discontinue this medicine.</p><p>Do not use Duetact if you are breastfeeding or are planning to breast-feed.</p><p><strong>Driving and using machines</strong><br />Alertness and reaction time may be impaired due to low or high blood sugar due to glimepiride, especially when beginning or after altering treatment, or when Duetact is not taken regularly. This may affect your ability to drive or use machines.</p><p>Take care if you experience abnormal vision.</p><p><strong>Duetact contains lactose monohydrate</strong><br />If you have been told by your doctor that you have intolerance to some sugars, contact your doctor before taking Duetact.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>The recommended dose is one tablet taken once daily shortly before or with the first main meal. If necessary your doctor may tell you to take a different dose. You should swallow the tablets with a glass of water.</p><p>If you have the impression that the effect of Duetact is too weak, talk to your doctor.</p><p>If you are following a special diet for diabetes, you should continue with this while you are taking Duetact.</p><p>Your weight should be checked at regular intervals; if your weight increases, inform your doctor.</p><p>Your doctor will ask you to have blood tests periodically during treatment with Duetact.</p><p><strong>If you take more Duetact than you should</strong><br />If you accidentally take too many tablets, or if someone else or a child takes your medicine, talk to a doctor or pharmacist immediately. Your blood sugar could fall below the normal level. The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness, nausea, coma or convulsion. Your blood sugar level can be increased by taking sugar. It is recommended that you carry some sugar lumps, sweets, biscuits or sugary fruit juice.&nbsp;</p><p><strong>If you forget to take Duetact</strong><br />Take Duetact daily as prescribed. However if you miss a dose, just carry on with the next dose as normal. Do not take a double dose to make up for a forgotten tablet.</p><p><strong>If you stop taking Duetact</strong><br />Duetact should be used every day to work properly. If you stop using Duetact, your blood sugar may go up. Talk to your doctor before stopping this treatment.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>In particular, patients have experienced the following serious side effects:<br />Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking Duetact. Signs and symptoms include blood in your urine, pain when urinating or a sudden need to urinate. If you experience any of these, talk to your doctor as soon as possible.</p><p>Hypoglycaemia (low blood sugar) has been reported uncommonly (may affect up to 1 in 100 people) in patients taking Duetact. The symptoms may include cold sweat, tiredness, headache, rapid heartbeat, hunger pangs, irritability, nervousness or nausea. It is important to know what symptoms to expect when hypoglycaemia (low blood sugar) occurs. Ask your doctor or pharmacist for more information if you are not sure how to recognise this and what you should do if you experience the symptoms.</p><p>Decrease in blood platelets (which increases risk of bleeding or bruising), red blood cells (which makes the skin pale and cause weakness or breathlessness) and white blood cells(which makes infections more likely) have been reported in patients taking Duetact rarely (may affect up to 1 in 1,000 people). If you experience this side effect, talk to your doctor as soon as possible. These problems generally get better after you stop taking Duetact.</p><p>Localised swelling (oedema) has also been experienced commonly (may affect up to 1 in 10 people) in patients taking Duetact in combination with insulin. If you experience this side effect, talk to your doctor as soon as possible.</p><p>Broken bones have been reported commonly (may affect up to 1 in 10 people) in women patients taking Duetact. If you experience this side effect, talk to your doctor as soon as possible.</p><p>Blurred vision due to swelling (or fluid) at the back of the eye (frequency cannot be estimated from the available data) has also been reported in patients taking Duetact. If you experience this symptom for the first time, talk to your doctor as soon as possible. Also, if you already have blurred vision and the symptom gets worse, talk to your doctor as soon as possible.</p><p>Allergic reactions have been reported (frequency cannot be estimated from the available data) in patients taking Duetact. If you have a serious allergic reaction, including hives and swelling of the face, lips, tongue, or throat that may cause difficulty in breathing or swallowing stop taking this medicine and talk to your doctor as soon as possible.</p><p>Some patients experienced the following side effects whilst taking pioglitazone and sulphonylureas, including glimepiride:<br /><strong>Common (may affect up to 1 in 10 people)</strong></p><ul><li>Weight gain</li><li>Dizziness</li><li>Gas</li><li>Respiratory infection</li><li>Numbness</li></ul><p><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Headache</li><li>Inflammation of the sinus (sinusitis)</li><li>Vertigo</li><li>Abnormal vision</li><li>Sweating</li><li>Tiredness</li><li>Difficulty sleeping (insomnia)</li><li>Decreased blood sugar</li><li>Sugar in urine</li><li>Proteins in urine</li><li>Increased appetite</li><li>Increase of an enzyme called lactic dehydrogenase (LDH)</li></ul><p><strong>Rare (may affect up to 1 in 1,000 people)</strong></p><ul><li>Noticeable changes in the blood</li></ul><p><strong>Very rare (may affect up to 1 in 10,000 people)</strong></p><ul><li>Liver disease</li><li>Allergic reactions including allergic shock</li><li>Feeling sick (nausea), vomiting and diarrhoea</li><li>Abdominal pain</li><li>Abdominal pressure</li><li>Feeling of fullness in the stomach</li><li>Sensitivity to light</li><li>Decrease in salt (sodium) concentrations in the blood</li></ul><p><strong>Not known (frequency can not be estimated from the available data)</strong></p><ul><li>Increase in liver enzymes</li><li>Itchy skin</li><li>Raised and itchy rash (hives)</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Store below 30&deg;C.<br />Do not use this medicine after the expiry date which is stated on the carton and the blister pack after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.<br />Do not throw away any medicines via waste water or household waste. Ask you pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Duetact 30 mg/4 mg contains</strong></p><ul><li>The active substances are pioglitazone and glimepiride. Each tablet contains 30 mg pioglitazone (as hydrochloride) and 4 mg glimepiride.</li><li>The other ingredients are cellulose microcrystalline, croscarmellose sodium, hydroxypropylcellulose, lactose monohydrate (see section 2 &lsquo;Duetact contains lactose monohydrate&rsquo;), magnesium stearate and polysorbate 80.</li></ul><p><strong>What Duetact 30 mg/2 mg contains</strong></p><ul><li>The active substances are pioglitazone and glimepiride. Each tablet contains 30 mg pioglitazone (as hydrochloride) and 2 mg glimepiride.</li><li>The other ingredients are cellulose microcrystalline, croscarmellose sodium, hydroxypropylcellulose, lactose monohydrate (see section 2 &lsquo;Duetact contains lactose monohydrate&rsquo;), magnesium stearate and polysorbate 80.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Duetact 30 mg/4 mg tablets
The tablets are white to off-white, round, convex and debossed with ‘4833 G’ on one face and ‘30/4’ on the other.  

The tablets are supplied in a white jar containing 30 tablets.

Duetact 30 mg/2 mg tablets
The tablets are white to off-white, round, convex and debossed with ‘4833 G’ on one face and ’30/2’ on the other. 

The tablets are supplied in a white jar containing 30 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder:</strong><br />Jazeera Pharmaceutical Industries (JPI)<br />Riyadh, Saudi Arabia, 11666 Riyadh, P.O.Box 106229<br />Phone No.: +966-11-207-8172<br />Fax: +966-11-207-8097<br />E-mail: medical@jpi.com.sa</p><p><strong>Manufacturer:</strong> &nbsp;</p><p>Takeda GmbH<br />Production Site Oranienburg<br />Lehnitzstrasse 70-98<br />16515 Oranienburg, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last approved in 09/2014, version 1.1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي ديوتاكت على بيوغليتازون وغليميبيريد والتي تعدّ أدوية مضادة للسكري، وتستخدم للسيطرة على مستوى السكر في الدم.</p><p>يتم استخدامه من قبل البالغين عندما يكون الميتفورمين غير مناسب لعلاج النوع 2 (غير المعتمد على الأنسولين) من السكري. عادةً ما يتطور داء السكري من النوع 2 في مرحلة البلوغ حيث يكون الجسم إما لا ينتج ما يكفي من الأنسولين (الهرمون الذي يتحكم في مستويات السكر في الدم)، أو لا يمكنه استخدام الأنسولين الذي ينتجه بشكل فعال.</p><p>يساعد ديوتاكت على التحكم في مستوى السكر في الدم عندما تعاني من مرض السكري النوع 2 عن طريق زيادة كمية الأنسولين المتاحة ومساعدة جسمك الاستفادة منه بشكل أفضل. سوف تحقق طبيبك ما إذا كان ديوتاكت يعمل بعد 3 إلى 6 أشهر من بدء تناوله.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>لا تتناول ديوتاكت إذا كنت تعاني من:</strong></p><ul><li dir="rtl">إذا كنت تعاني من حساسية لبيوغليتازون، غليميبيريد، السلفونيل يوريا أو السلفوناميدات الأخرى، أو أي من المكونات الأخرى في هذا الدواء (مدرجة في القسم 6).</li><li dir="rtl">إذا كنت تعاني أو عانيت في الماضي من فشل القلب.</li><li dir="rtl">إذا كنت تعاني من أمراض في الكبد.</li><li dir="rtl">إذا كنت تعاني من الحماض الكيتوني السكري (مضاعفات مرض السكري مع فقدان الوزن السريع، أو الغثيان أو القيء).</li><li dir="rtl">إذا كنت تعاني من مشاكل حادة في الكلى.</li><li dir="rtl">إذا كنت تعاني أو عانيت فيما مضى من سرطان المثانة.</li><li dir="rtl">إذا كنت تعاني من وجود دم في البول لم يتحقق طبيبك منه.</li><li dir="rtl">إذا كنت تعاني من السكري المعتمد على الأنسولين (النوع 1).</li><li dir="rtl">إذا كنت في غيبوبة السكري.</li><li dir="rtl">إذا كنت حاملاً.</li><li dir="rtl">إذا كنت تقومين بالرضاعة الطبيعية.&nbsp;</li></ul><p><strong>احتياطات وتحذيرات</strong>&nbsp;</p><p>قم باستشارة طبيبك أو الصيدلاني قبل البدء بتناول ديوتاكت (انظر أيضا القسم 4).&nbsp;</p><ul><li dir="rtl">إذا كنت تعاني من مشاكل في القلب. إن بعض المرضى الذين يعانون من داء السكري النوع 2 على المدى الطويل وأمراض القلب أو السكتة الدماغية السابقة الذين عولجوا بالبيوغليتازون والأنسولين معا شهدوا تطور قصور القلب لديهم. أبلغ الطبيب في أقرب وقت ممكن إذا لاحظت علامات فشل القلب مثل ضيق غير معتاد في التنفس أو زيادة سريعة في الوزن أو تورم موضعي (وذمة).&nbsp;</li><li dir="rtl">إذا كنت تعاني من احتباس المياه (احتباس السوائل)&nbsp;أو مشاكل قصور القلب وخاصة إذا كنت أكبر سنا من 75 عاماً. إذا كنت تأخذ الأدوية المضادة للالتهابات والتي يمكن أيضا أن تسبب احتباس السوائل والتورم، يجب عليك أيضا إخبار الطبيب.&nbsp;</li><li dir="rtl">إذا كنت تعاني من نوع خاص من مرض سكري العيون الذي يسمى وذمة البقعة الصفراء (تورم الجزء الخلفي من العين).</li><li dir="rtl">إذا كنت تعاني من مشكلة في الكبد. يجب عليك قبل البدء بتناول ديوتاكت أخذ عينة دم لفحص وظائف الكبد. وينبغي تكرار هذا الفحص على فترات. يجب إبلاغ الطبيب في أقرب وقت ممكن إذا تطورت لديك أعراض تشير إلى مشكلة في الكبد (مثل الشعور بالغثيان دون سبب، والتقيؤ، آلام في البطن، والتعب، وفقدان الشهية و/أو البول الداكن)&nbsp;حيث يجب التحقق من وظيفة الكبد.</li><li dir="rtl">إذا كنت تعانين من خراجات على المبايض (متلازمة المبيض متعدد الكيسات)&nbsp;قد يكون هناك زيادة احتمال الحمل لأنه قد تحدث لديك إباضة مرة أخرى عندتناول ديوتاكت. إذا انطبق هذا عليك، استخدمي وسائل منع الحمل المناسبة لتجنب احتمال حدوث حمل غير مخطط له.</li><li dir="rtl">إذا كنت تأخذ أدوية أخرى لعلاج مرض السكري.</li><li dir="rtl">إذا كنت تعاني من مشاكل مع الأنزيم الخاص بك الذي يسمى غلوكوز -6- فوسفوديهايدروجيناز حيث أنه يمكن أن يقلل عدد خلايا الدم الحمراء لديك. قد تواجه أيضا انخفاض في تعداد الدم (الأنيميا). قد يجري طبيبك فحوصات دم لرصد مستويات خلايا الدم ووظيفة الكبد لديك.&nbsp;</li></ul><p><em>نقص السكر في الدم </em></p><p>يمكن أن تنخفض نسبة السكر في الدم أقل من المستوى العادي عند تناول ديوتاكت. من المهم معرفة ماهية الأعراض التي يمكن توقعها عند حدوث انخفاض السكر في الدم. اسأل طبيبك أو الصيدلي للحصول على مزيد من المعلومات إذا لم تكن متأكدا من كيفية معرفة ذلك. قد تتضمن الأعراض التعرق البارد، والتعب، والصداع، وسرعة ضربات القلب، وتقلصات الجوع، والتهيج، والعصبية أو الغثيان. أخبر طبيبك إذا لاحظت حدوث مثل هذه الأعراض. يجب فحص مستوى السكر في الدم والبول بانتظام.</p><p><em>كسور العظام</em></p><p>تمت ملاحظة حدوث عدد أكبر من كسور العظام لدى المرضى، وخاصة النساء اللواتي يتناولن بيوغليتازون. سيأخذ طبيبك ذلك في عين الاعتبار عند علاج مرض السكري لديك.&nbsp;</p><p><strong>الأطفال والمراهقين</strong></p><p>لا ينصح باستخدامه من قبل الأطفال والمراهقين ما دون سن 18 سنة.</p><p><strong>تناول ديوتاكت مع الأدوية الأخرى</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تأخذ أو أخذت مؤخرا أو قد تأخذ أي أدوية أخرى. وذلك لأن بعض الأدوية يمكن أن تضعف أو تعزز تأثير ديوتاكت على مستوى السكر في دمك.</p><p>قد تزيد الأدوية التالية من تأثير ديوتاكت في خفض نسبة السكر في الدم. قد يؤدي ذلك إلى مخاطر حدوث نقص سكر الدم (انخفاض نسبة السكر في الدم):&nbsp;</p><ul><li dir="rtl">جيمفيبروزيل وفايبرات (لخفض مستوى الكوليسترول المرتفع)</li><li dir="rtl">الانسولين، والميتفورمين أو أدوية أخرى لعلاج مرض السكري</li><li dir="rtl">الفينيلبوتازون، آزابروبازون والأوكسيفين بوتازون، والأدوية المشابهة للأسبرين (لعلاج الألم والالتهاب)&nbsp;</li><li dir="rtl">السلفوناميدات طويلة المفعول، التتراسيكلين، الكلورامفينيكول، فلوكونازول، ميكونازول، الكينولون، كلاريثروميسين (لعلاج الالتهابات البكتيرية أو الفطرية).</li><li dir="rtl">الستيرويدات الابتنائية (لدعم بناء العضلات)&nbsp;أو علاج هرمونات الذكورة البديلة.</li><li dir="rtl">فلوكستين، مثبطات أكسيداز أحادي الأمين (لعلاج الاكتئاب).</li><li dir="rtl">مثبطات إنزيم محول الأنجيوتنسين، سيمباثوليتيكس، ديسوبيراميد، بنتوكسيفيلين، مشتقات الكومارين مثل الوارفارين (لعلاج اضطرابات القلب أو الدم).</li><li dir="rtl">الوبيورينول، بروبينسيد، سولفينبيرازون (لعلاج النقرس).</li><li dir="rtl">سيكلوفوسفاميد، إيفوسفاميد، تروفوسفاميد، (لعلاج السرطان).</li><li dir="rtl">فينفلورامين (لتخفيض الوزن).</li><li dir="rtl">تريتوكالين (لعلاج الحساسية).</li></ul><p>قد تقلل الأدوية التالية من تأثير ديوتاكت في خفض نسبة السكر في الدم. قد يؤدي ذلك إلى خطر ارتفاع السكر في الدم:</p><ul><li dir="rtl">الاستروجين، بروجستيرون (الهرمونات الجنسية الأنثوية).</li><li dir="rtl">مدرات البول والملح الثيازيدية تسمى أيضا أقراص التبول (لعلاج ارتفاع ضغط الدم).</li><li dir="rtl">ليفوثيروكسين (لتحفيز الغدة الدرقية).</li><li dir="rtl">الغلوكوكوريكويدات (لعلاج الحساسية والالتهاب).&nbsp;</li><li dir="rtl">الكلوربرومازين وغيرها من مشتقات الفينوثيازين (لعلاج الاضطرابات النفسية الشديدة).</li><li dir="rtl">الأدرينالين والمحاكيات الودية (لزيادة ضربات القلب، لعلاج الربو أو احتقان الانف، السعال ونزلات البرد أو لاستخدامها في حالات الطوارئ التي تهدد الحياة).</li><li dir="rtl">حمض النيكوتينيك (لعلاج ارتفاع مستوى الكوليسترول).</li><li dir="rtl">استخدام الملينات طويل المدى (لعلاج الإمساك).</li><li dir="rtl">الفينيتوين (لعلاج التشنجات).</li><li dir="rtl">الباربيتورات (لعلاج مشاكل النوم والعصبية).</li><li dir="rtl">أزيتازولاميد (لعلاج زيادة الضغط في العين والذي يسمى أيضا الزرق).</li><li dir="rtl">ديازوكسيد (لعلاج ارتفاع ضغط الدم أو انخفاض السكر في الدم).</li><li dir="rtl">ريفامبيسين (لعلاج الالتهابات والسل).</li><li dir="rtl">الجلوكاغون (لعلاج مستويات انخفاض سكر الدم الشديدة).</li></ul><p>قد تزيد الأدوية التالية أو تقلل من نسبة السكر في الدم أو تقلل تأثير ديوتاكت:</p><ul><li dir="rtl">مضادات&nbsp;H2&nbsp;(لعلاج قرحة المعدة).</li><li dir="rtl">حاصرات بيتا، الكلونيدين، غوانيثيدين وريزيربين (لعلاج ارتفاع ضغط الدم أو فشل القلب) قد تؤدي هذه أيضا إلى إخفاء علامات نقص السكر في الدم، لذا فإن الرعاية الخاصة مطلوبة عند أخذ هذه الأدوية.</li></ul><p>قد يؤدي ديوتاكت إما إلى زيادة أو إضعاف آثار الأدوية التالية:</p><ul><li dir="rtl">مشتقات الكومارين مثل الوارفارين (لإبطاء أو وقف تخثر الدم)&nbsp;</li></ul><p>أخبر طبيبك أو الصيدلي إذا كنت تأخذ أي من هذه. سيتم فحص نسبة السكر في الدم، وقد تحتاج إلى تغيير جرعة ديوتاكت.</p><p><strong>تناول ديوتاكت مع الطعام والشراب والكحول</strong></p><p>تجنب تناول الكحول أثناء تناول ديوتاكت بما أن الكحول قد تزيد أو تنقص من فعل ديوتاكت في خفض السكر في الدم بطريقة لا يمكن التنبؤ بها.</p><p><strong>الحمل والإرضاع</strong></p><p>لا تستخدمي ديوتاكت إذا كنت حاملاً. يجب إخبار الطبيب إذا كنتِ حاملا أو تعتقدين أنك كذلك أو تخططين للحمل. سينصحك الطبيب بالتوقف عن تناول هذا الدواء.</p><p>لا تستخدمي ديوتاكت إذا كنت تقومين بالرضاعة الطبيعية أو تخططين لذلك.</p><p><strong>تأثير ديوتاكت على القيادة واستخدام الآلات</strong></p><p>قد يضطرب وقت رد الفعل واليقظة نظرا لانخفاض أو ارتفاع السكر في الدم بسبب الغليميبيريد، وخصوصا عندما تبدأ أو بعد تغيير العلاج، أو عند عدم تناول ديوتاكت بانتظام. قد يؤثر هذا على قدرتك على القيادة أو استخدام الآلات.يجب الحذر اذا كنت تعاني من رؤية غير واضحة.&nbsp;</p><p><strong>يحتوي ديوتاكت على مونوهيدرات اللاكتوز</strong></p><p>إذا أخبرك الطبيب أنك تعاني من عدم تحمل لبعض السكريات، اتصل به قبل قبل تناول ديوتاكت.&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يرجى استخدام ديوتاكت تماما كما وصفه الطبيب أو استشارة الطبيب أو الصيدلي إذا كنت غير متأكد.</p><p>الجرعة الموصى بها هي قرص واحد يؤخذ مرة يوميا بعد وقت قصير من أول وجبة أو أثناء تناولها. سيخبرك طبيبك إذا لزم الأمر أن تتناول جرعة مختلفة. يجب أن تبتلع الأقراص مع كأس من الماء.</p><p>إذا شعرت أن تأثير ديوتاكت ضعيف جدا أخبر الطبيب.</p><p>إذا كنت تتبع نظام غذائي خاص لمرضى السكري، يجب أن تستمر به أثناء تناولك ديوتاكت.</p><p>يجب فحص وزنك على فترات منتظمة؛ أخبر طبيبك إذا كان وزنك يزيد. سيطلب منك طبيبك إجراء اختبارات الدم بصورة دورية خلال فترة العلاج بديوتاكت.</p><p><strong>الجرعة الزائدة من ديوتاكت</strong></p><p>إذا أخذت الكثير من الأقراص دون قصد، أو إذا أخذ شخص آخر أو طفل الدواء، تحدث إلى الطبيب أو الصيدلي فورا. قد تنخفض نسبة السكر في الدم دون المستوى العادي. قد تتضمن الأعراض عرق بارد، أو تعب، أو صداع، أو سرعة ضربات القلب، آلام الجوع، أو تهيج أو عصبية أو غثيان أو غيبوبة أو تشنج.</p><p>ويمكن زيادة مستوى السكر في الدم عن طريق تناول السكر. فمن المستحسن أن تحمل بعض مكعبات السكر، أو الحلويات، أو البسكويت أو عصير الفواكه السكري.</p><p><strong>نسيان تناول جرعة ديوتاكت</strong></p><p>تناول ديوتاكت يوميا على النحو الموصوف لك. ولكن إذا نسيت تناول جرعة، استمر في الجرعة التالية كالمعتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p><strong>التوقف عن استخدام ديوتاكت</strong></p><p>ينبغي أن يستخدم ديوتاكت كل يوم ليعمل بشكل صحيح. إذا توقفت عن استخدام ديوتاكت فقد ترتفع نسبة السكر في الدم. تحدث إلى طبيبك قبل وقف هذا العلاج.إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، قد يعاني بعض المرضى من أعراض نتيجة تناول هذا الدواء.على وجه الخصوص، شهد المرضى الآثار الجانبية الخطيرة التالية:</p><p>حدث سرطان المثانة بشكل غير مألوف (قد يؤثر على ما يصل إلى 1 من كل 100 شخص)&nbsp;لدى المرضى الذين يتناولون ديوتاكت. تشمل علاماته وأعراضه وجود الدم في البول، وألم عند التبول أو الحاجة المفاجئة للتبول. إذا عانيت من أي منها، تحدث الى الطبيب في أقرب وقت ممكن.</p><p>تم الإبلاغ عن حدوث نقص سكر الدم (انخفاض نسبة السكر في الدم)&nbsp;بشكل غير مألوف (قد يؤثر على ما يصل إلى 1 من كل 100 شخص)&nbsp;لدى المرضى الذين يتناولون ديوتاكت. قد تتضمن أعراضه عرق بارد، وتعب، وصداع، وسرعة ضربات القلب، آلام الجوع، وتهيج، وعصبية أو غثيان. من المهم أن تعرف ما هي الأعراض التي يمكن توقعها عندما يحدث نقص سكر الدم (انخفاض نسبة السكر في الدم). اسأل طبيبك أو الصيدلي للحصول على مزيد من المعلومات إذا لم تكن متأكدا من كيفية معرفتها وما يجب عليك القيام به عند الإصابة بهذه الأعراض.</p><p>تم الإبلاغ عن حدوث انخفاض في الصفائح الدموية (مما يزيد من خطر حدوث نزيف أو كدمات)، وفي خلايا الدم الحمراء (وهو ما يجعل الجلد شاحب ويسبب ضعف أو ضيق التنفس)&nbsp;وفي خلايا الدم البيضاء (مما يجعل حدوث الالتهابات أكثر احتمالا)&nbsp;لدى المرضى الذين يتناولون ديوتاكت بشكل نادر (قد يؤثر على ما يصل إلى 1 من كل 1000 شخص). إذا عانيت من هذه الآثار الجانبية، تحدث الى الطبيب في أقرب وقت ممكن. تتحسن هذه المشاكل عموما بعد التوقف عن تناول ديوتاكت.</p><p>تم الإبلاغ أيضا عن حدوث تورم موضعي (وذمة)&nbsp;(قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص)&nbsp;لدى المرضى الذين يتناولون ديوتاكت بالتزامن مع الأنسولين. إذا عانيت من هذه الآثار الجانبية، تحدث الى الطبيب في أقرب وقت ممكن.</p><p>وقد تم الإبلاغ عن حدوث كسور في العظام بشكل شائع (قد يؤثر على ما يصل إلى 1 من كل 10 أشخاص)&nbsp;لدى المرضى النساء اللواتي يتناولن ديوتاكت. إذا عانيت من هذه الآثار الجانبية، تحدث الى الطبيب في أقرب وقت ممكن.</p><p>كما تم الإبلاغ عن حدوث عدم وضوح الرؤية بسبب التورم (أو وجود السوائل)&nbsp;في الجزء الخلفي من العين (لا يمكن تقدير الشيوع من البيانات المتاحة)&nbsp;لدى المرضى الذين يتناولون ديوتاكت. إذا عانيت من هذه الأعراض لأول مرة، تحدث الى الطبيب في أقرب وقت ممكن. إذا كنت تعاني بالفعل من عدم وضوح الرؤية وكانت الأعراض تزداد سوءا، تحدث الى الطبيب في أقرب وقت ممكن.</p><p>تم الإبلاغ عن حدوث الحساسية (لا يمكن تقدير الشيوع من البيانات المتاحة)&nbsp;لدى المرضى الذين يتناولون ديوتاكت. إذا كنت تعاني من الارتكاس التحسسي الخطير، بما في ذلك الطفح وتورم في الوجه والشفتين واللسان، أو الحلق والتي قد تسبب صعوبة في التنفس أو البلع، توقف عن تناول هذا الدواء واستشر الطبيب في أقرب وقت ممكن.</p><p>شهد بعض المرضى الآثار الجانبية التالية أثناء تناول بيوغليتازون وسلفونيل يوريا، بما في ذلك الغليميبيريد:</p><p><strong>شائعة (قد تؤثر على 1 من كل 10 أشخاص):</strong></p><ul><li dir="rtl">زيادة الوزن</li><li dir="rtl">الدوخة</li><li dir="rtl">الغازات</li><li dir="rtl">التهاب الجهاز التنفسي</li><li dir="rtl">الخدر</li></ul><p><strong>غير شائعة (قد تؤثر على 1 من كل 100 شخص): </strong></p><ul><li dir="rtl">صداع</li><li dir="rtl">التهاب الجيوب الأنفية</li><li dir="rtl">دوار</li><li dir="rtl">رؤية غير طبيعية&nbsp;</li><li dir="rtl">تعرق</li><li dir="rtl">تعب</li><li dir="rtl">صعوبة في النوم (أرق)&nbsp;</li><li dir="rtl">انخفاض السكر في الدم</li><li dir="rtl">وجود سكر في البول</li><li dir="rtl">وجود بروتينات في البول</li><li dir="rtl">زيادة الشهية</li><li dir="rtl">زيادة إنزيم يسمى نازعة اللبنيك</li></ul><p><strong>نادرة (قد تؤثر على 1 من كل 1000 شخص): </strong></p><ul><li>تغيرات ملحوظة في الدم</li></ul><p><strong>نادرة جدا (قد تؤثر على 1 من كل 10000 شخص):</strong></p><ul><li dir="rtl">أمراض الكبد</li><li dir="rtl">الحساسية بما في ذلك الصدمة التحسسية</li><li dir="rtl">الشعور بالغثيان، التقيؤ، الإسهال</li><li dir="rtl">آلام في البطن</li><li dir="rtl">ضغط في البطن</li><li dir="rtl">الشعور بالامتلاء في المعدة</li><li dir="rtl">الحساسية للضوء</li><li dir="rtl">نقص تركيزات الملح (الصوديوم)&nbsp;في الدم.</li></ul><p><strong>غير معروفة (لا يمكن تقدير الشيوع من البيانات المتاحة):</strong></p><ul><li dir="rtl">زيادة أنزيمات الكبد</li><li dir="rtl">حكة في الجلد</li><li dir="rtl">طفح وحكة</li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدا عن مرأى ومتناول الأطفال.</p><p>يحفظ عند درجة حرارة اقل من 30&deg; درجة مئوية.&nbsp;</p><p>لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الخارجية. يشير تاريخ الإنتهاء إلى اليوم الأخير من ذلك الشهر.</p><p>لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p>لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة اليها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هي محتويات ديوتاكت 30 مغ/4 مغ</strong></p><ul><li dir="rtl">المادة الفعالة هي بيوغليتازون وغليميبيريد. يحتوي كل قرص على 30 مغ بيوغليتازون (كهيدروكلوريد)&nbsp;و4 مغ غليميبيريد.</li><li dir="rtl">المكونات الأخرى هي ميكروكريستالين السليلوز، كروسكارميلوز الصوديوم، هيدروكسي بروبيل السليلوز، مونوهيدرات اللاكتوز (انظر القسم 2 يحتوي ديوتاكت على مونوهيدرات اللاكتوز)، ستيرات المغنيسيوم وبوليسوربات 80.&nbsp;</li></ul><p><strong>ما هي محتويات ديوتاكت 30 مغ/2 مغ</strong></p><ul><li dir="rtl">المادة الفعالة هي بيوغليتازون وغليميبيريد. يحتوي كل قرص على 30 مغ بيوغليتازون (كهيدروكلوريد)&nbsp;و2 مغ غليميبيريد.</li><li dir="rtl">المكونات الأخرى هي ميكروكريستالين السليلوز، كروسكارميلوز الصوديوم، هيدروكسي بروبيل السليلوز، مونوهيدرات اللاكتوز (انظر القسم 2 يحتوي ديوتاكت على مونوهيدرات اللاكتوز)، ستيرات المغنيسيوم وبوليسوربات 80.</li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right"><strong>أقراص ديوتاكت 30 مغ/4 مغ</strong></p><p style="text-align:right">الأقراص ذات لون أبيض مائل إلى الصفرة، مستديرة ومحدبة ومحفور على أحد وجهيها&nbsp;&quot;4833G&quot;&nbsp;وعلى الوجه الآخر &quot;30/4&quot; تأتي الأقراص في علبة بيضاء تحتوي على 30 قرص.</p><p style="text-align:right">قد لا يتم تسويق جميع أحجام العبوات.</p><p style="text-align:right"><strong>أقراص ديوتاكت 30 مغ/2 مغ </strong></p><p style="text-align:right">الأقراص ذات لون أبيض مائل إلى الصفرة، مستديرة ومحدبة ومحفور على أحد وجهيها &quot;4833G&quot; وعلى الوجه الآخر &quot;30/2&quot; تأتي الأقراص في علبة بيضاء تحتوي على 30 قرص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>حامل رخصة التسويق</strong></p><p>الجزيرة للصناعات الدوائية</p><p>الرياض 11666، المملكة العربية السعودية، صندوق بريد 106229</p><p>هاتف: 966112078172+</p><p>فاكس: 966112078097+</p><p>بريد إلكتروني: medical@jpi.com.sa</p><p><strong>الشركة المصنّعة&nbsp;</strong></p><p>شركة تاكيدا ذات المسؤولية المحدودة</p><p>موقع الإنتاج أورانينبورغ</p><p>&nbsp;Lehnitzstrasse&nbsp;98-70<br />16515 أورانينبورغ، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ 2016/02، رقم النسخة: 1.1.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Duetact 30 mg/4 mg Tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 30 mg pioglitazone (as hydrochloride) and 4 mg of glimepiride.

Excipients with known effect Each tablet contains approximately 177 mg of lactose monohydrate (see section 4.4). 

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet. 

White to off-white convex, round, 8.0 mm diameter, 4.7 mm thick, tablet debossed with “4833G” on one side and “30/4” on the other.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Duetact is indicated as second line treatment of adult patients with type 2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride.</p><p>After initiation of therapy with pioglitazone, patients should be reviewed after 3 to 6 months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, pioglitazone should be discontinued. In light of potential risks with prolonged therapy, prescribers should confirm at subsequent routine reviews that the benefit of pioglitazone is maintained (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Posology</strong><br />The recommended dose of Duetact is one tablet taken once daily.</p><p>If patients report hypoglycaemia, the dose of Duetact should be reduced or free combination therapy should be considered.</p><p>If patients are receiving pioglitazone in combination with a sulphonylurea other than glimepiride, patients should be stabilised with concomitant pioglitazone and glimepiride before switching to Duetact.</p><p><u>Special population</u><br /><em>Elderly</em><br />Physicians should start treatment with the lowest available dose and increase the dose gradually, particularly when pioglitazone is used in combination with insulin (see section 4.4 Fluid retention and cardiac failure).</p><p><em>Renal impairment</em><br />Duetact should not be used in patients with severe renal function disorders (creatinine clearance &lt; 30 ml/min, see section 4.3).</p><p><em>Hepatic impairment</em><br />Duetact should not be used in patients with hepatic impairment (see section 4.3 and 4.4).</p><p><em>Paediatric population</em><br />The safety and efficacy of Duetact in children and adolescents under 18 years of age have not been established. No data are available.</p><p><strong>Method of administration</strong><br />The tablets are taken orally shortly before or with the first main meal. The tablets should be swallowed with a glass of water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Duetact is contraindicated in patients with:
• Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or other sulphonylureas or sulphonamides.
• Cardiac failure or history of cardiac failure (NYHA stages I to IV).
• Current bladder cancer or a history of bladder cancer.
• Uninvestigated macroscopic haematuria.
• Hepatic impairment.
• Type 1 diabetes mellitus.
• Diabetic coma.
• Diabetic ketoacidosis.
• Severe renal function disorders (creatinine clearance < 30 ml/min).
• Pregnancy.
• Breast-feeding.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no clinical trial experience of other oral anti-hyperglycaemic medicinal products added to treatment with Duetact or concomitantly administered glimepiride and pioglitazone.</p><p><u>Hypoglycaemia</u><br />When meals are taken at irregular hours or skipped altogether, treatment with Duetact may lead to hypoglycaemia due to the sulphonylurea component. Symptoms can almost always be promptly controlled by immediate intake of carbohydrates (sugar). Artificial sweeteners have no effect.</p><p>It is known from other sulphonylureas that, despite initially successful countermeasures, hypoglycaemia may recur. Severe hypoglycaemia or prolonged hypoglycaemia, only temporarily controlled by the usual amounts of sugar, require immediate medical treatment and occasionally hospitalisation.</p><p>Treatment with Duetact requires regular monitoring of glycaemic control.</p><p><u>Fluid retention and cardiac failure</u><br />Pioglitazone can cause fluid retention, which may exacerbate or precipitate heart failure. When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start with the lowest available dose of pioglitazone and increase the dose gradually. Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs, including selective COX-2 inhibitors. Duetact should be discontinued if any deterioration in cardiac state occurs.</p><p>A cardiovascular outcome study of pioglitazone has been performed in patients under 75 years with type 2 diabetes mellitus and pre-existing major macrovascular disease. Pioglitazone or placebo was added to existing antidiabetic and cardiovascular therapy for up to 3.5 years. This study showed an increase in reports of heart failure, however this did not lead to an increase in mortality in this study.&nbsp;</p><p><u>Elderly</u><br />Combination use with insulin should be considered with caution in the elderly because of increased risk of serious heart failure.<br />In light of age- related risks (especially bladder cancer, fractures and heart failure), the balance of benefits and risks should be considered carefully both before and during treatment in the elderly.</p><p><u>Bladder cancer</u><br />Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical trials with pioglitazone (19 cases from 12506 patients, 0.15%) than in control groups (7 cases from 10212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were 7 cases (0.06%) on pioglitazone and 2 cases (0.02%) in control groups. Available epidemiological data also suggest a small increased risk of bladder cancer in diabetic patients treated with pioglitazone in particular in patients treated for the longest durations and with the highest cumulative doses. A possible risk after short term treatment cannot be excluded.</p><p>Risk factors for bladder cancer should be assessed before initiating pioglitazone treatment (risks include age, smoking history, exposure to some occupational or chemotherapy agents e.g. cyclophosphamide or prior radiation treatment in the pelvic region). Any macroscopic haematuria should be investigated before starting pioglitazone therapy.</p><p>Patients should be advised to promptly seek the attention of their physician if macroscopic haematuria or other symptoms such as dysuria or urinary urgency develop during treatment.</p><p><u>Liver function</u><br />There have been rare reports of elevated liver enzymes and hepatocellular dysfunction during post-marketing experience with pioglitazone and glimepiride (see section 4.8). Although in very rare cases fatal outcome has been reported, causal relationship has not been established. It is recommended, therefore, that patients treated with Duetact undergo periodic monitoring of liver enzymes. Liver enzymes should be checked prior to the initiation of therapy with Duetact in all patients. Therapy with Duetact should not be initiated in patients with increased baseline liver enzyme levels (ALT &gt; 2.5 X upper limit of normal) or with any other evidence of liver disease.</p><p>Following initiation of therapy with Duetact, it is recommended that liver enzymes be monitored periodically based on clinical judgement. If ALT levels are increased to 3 X upper limit of normal during Duetact therapy, liver enzyme levels should be reassessed as soon as possible. If ALT levels remain &gt; 3 X the upper limit of normal, therapy should be discontinued. If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. The decision whether to continue the patient on therapy with Duetact should be guided by clinical judgement pending laboratory evaluations. If jaundice is observed, the medicinal product should be discontinued.</p><p><u>Weight gain</u><br />In clinical trials with pioglitazone and sulphonylurea monotherapy or in combination there was evidence of dose related weight gain, which may be due to fat accumulation and in some cases associated with fluid retention. In some cases weight increase may be a symptom of cardiac failure therefore weight should be closely monitored. Part of the treatment of diabetes is dietary control. Patients should be advised to adhere strictly to a calorie-controlled diet.</p><p><u>Haematology</u><br />Rare changes in haematology have been observed with glimepiride treatment (see section 4.8). Treatment with Duetact therefore requires regular haematological monitoring (especially leucocytes and platelets).</p><p>During therapy with pioglitazone there was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction), consistent with haemodilution. Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone.</p><p>Treatment of patients with G6PD-deficiency with sulfonylurea agents can lead to haemolytic anaemia. Since glimepiride belongs to the chemical class of sulfonylurea medicinal products, caution should be used in patients with G6PD-deficiency and a non sulfonylurea alternative should be considered.</p><p><u>Eye disorders</u><br />Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. Many of these patients reported concurrent peripheral oedema. It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients report disturbances in visual acuity; an appropriate ophthalmological referral should be considered.</p><p><u>Polycystic ovarian syndrome</u><br />As a consequence of enhancing insulin action, pioglitazone treatment in patients with polycystic ovarian syndrome may result in resumption of ovulation. These patients may be at risk of pregnancy. Patients should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occurs, the treatment should be discontinued (see section 4.6).</p><p><u>Others</u><br />An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions reports of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years.</p><p>Fractures were observed in 2.6% of women taking pioglitazone compared to 1.7% of women treated with a comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).</p><p>The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use.</p><p>In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).</p><p>Some epidemiological studies have suggested a similarly increased risk of fracture in both men and women.</p><p>The risk of fractures should be considered in the long term care of patients treated with pioglitazone.</p><p>Pioglitazone should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). Glycaemic control should be monitored closely. Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5).</p><p>The tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There have been no formal interaction studies for Duetact, however, the concomitant use of the active substances in patients in clinical use has not resulted in any unexpected interactions. The following statements reflect the information available on the individual active substances (pioglitazone and glimepiride).</p><p><u>Pioglitazone</u><br />Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. A decrease in the dose of pioglitazone may be needed when gemfibrozil is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4). Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. The pioglitazone dose may need to be increased when rifampicin is concomitantly administered. Close monitoring of glycaemic control should be considered (see section 4.4).</p><p>Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Co-administration of pioglitazone with sulphonylureas does not appear to affect the pharmacokinetics of the sulphonylurea. Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. <em>In vitro</em> studies have shown no inhibition of any subtype of cytochrome P450. Interactions with substances metabolised by these enzymes, e.g. oral contraceptives, cyclosporin, calcium channel blockers, and HMGCoA reductase inhibitors are not to be expected.</p><p><strong>Glimepiride</strong><br />If glimepiride is taken simultaneously with certain other medicinal products, both undesired increases and decreases in the hypoglycaemic action of glimepiride can occur. For this reason, other medicinal products should only be taken with Duetact with the knowledge (or at the prescription) of the doctor.</p><p>Based on the experience with glimepiride and with other sulphonylureas the following interactions have to be mentioned.</p><p>Potentiation of the blood-glucose-lowering effect and, thus, in some instances hypoglycaemia may occur when one of the following active substances is taken, for example:</p><ul><li>Phenylbutazone, azapropazone and oxyfenbutazone</li><li>Insulin and oral antidiabetic products</li><li>Metformin</li><li>Salicylates and p-amino-salicylic acid</li><li>Anabolic steroids and male sex hormones</li><li>Chloramphenicol</li><li>Clarithromycin</li><li>Coumarin anticoagulants</li><li>Disopyramide</li><li>Fenfluramine</li><li>Fibrates</li><li>ACE inhibitors</li><li>Fluoxetine</li><li>Allopurinol</li><li>Sympatholytics</li><li>Cyclo-, tro-and iphosphamides</li><li>Sulphinpyrazone</li><li>Certain long-acting sulphonamides</li><li>Tetracyclines</li><li>MAO-inhibitors</li><li>Quinolone antibiotics</li><li>Probenecid</li><li>Miconazole</li><li>Pentoxyfylline (high dose parenteral)</li><li>Tritoqualine</li><li>Fluconazole.</li></ul><p>Weakening of the blood-glucose-lowering effect and, thus raised blood glucose levels may occur when one of the following active substances is taken, for example:</p><ul><li>Oestrogens and progestagens</li><li>Saluretics, thiazide diuretics</li><li>Thyroid stimulating agents, glucocorticoids</li><li>Phenothiazine derivatives, chlorpromazine</li><li>Adrenaline and sympathicomimetics</li><li>Nicotinic acid (high doses) and nicotinic acid derivatives</li><li>Laxatives (long-term use)</li><li>Phenytoin, diazoxide</li><li>Glucagon, barbiturates and rifampicin</li><li>Acetozolamide.</li></ul><p>H2 antagonists, betablockers, clonidine and reserpine may lead to either potentiation or weakening of the blood glucose lowering effect.</p><p>Under the influence of sympatholytic active substances such as betablockers, clonidine, guanethidine and reserpine, the signs of adrenergic counterregulation to hypoglycaemia may be reduced or absent.<br /><br />Alcohol intake may potentiate or weaken the hypoglycaemic action of glimepiride in an unpredictable fashion.</p><p>Glimepiride may either potentiate or weaken the effects of coumarin derivatives.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females</u><br />Duetact is not recommended in women of childbearing potential not using contraception. If a patient wishes to become pregnant, treatment with Duetact should be discontinued.</p><p><u>Pregnancy</u><br />Pregnancy category C.</p><p>There are no adequate data from the use of pioglitazone in pregnant women. Studies of pioglitazone in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown.</p><p>There are no adequate data from the use of glimepiride in pregnant women. Animal studies have shown reproductive toxicity which was most likely related to the pharmacological action (hypoglycaemia) of glimepiride.</p><p>Duetact is contraindicated during pregnancy (see section 4.3). If a pregnancy occurs, treatment with Duetact should be discontinued.</p><p><u>Breast-feeding</u><br />Sulphonylurea-derivatives like glimepiride pass into the breast milk. Pioglitazone has been shown to be present in the milk of lactating rats. It is not known whether pioglitazone is secreted in human milk.</p><p>Duetact is contra-indicated during breast-feeding (see section 4.3).</p><p><u>Fertility</u><br />In animal fertility studies with pioglitazone, there was no effect on copulation, impregnation or fertility index.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Duetact has minor influence on the ability to drive and use machines. The patient&rsquo;s ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia from glimepiride or, for example, as a result of visual impairment. This may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or using machines).</p><p>Patients should be advised to take precautions to avoid hypoglycaemia whilst driving. This is particularly important in those who have reduced or absent awareness of the warnings of hypoglycaemia or have frequent episodes of hypoglycaemia. It should be considered whether it is advisable to drive or use machines in these circumstances.</p><p>Patients who experience visual disturbance should be cautious when driving or using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />Clinical trials have been conducted with co-administered pioglitazone and glimepiride (see section 5.1) and bioequivalence of Duetact with co-administered pioglitazone and glimepiride has also been demonstrated (see section 5.2). Hypoglycaemic reactions mostly occur immediately due to the sulphonylurea component of Duetact. Symptoms can almost always be promptly controlled by immediate intake of carbohydrates (sugar). This is a serious reaction which may occur uncommonly (&ge; 1/1,000 to &lt; 1/100) (see section 4.4). Moderate to severe thrombocytopenia, leucopenia, erythrocytopenia, granulocytopenia, agranulocytosis, haemolytic anaemia and pancytopenia may occur rarely (&ge; 1/10,000 to &lt;1/1,000) (see section 4.4). Other reactions such as bone fracture, weight increase and oedema may occur commonly (&ge; 1/100 to &lt; 1/10) (see section 4.4).</p><p><u>Tabulated list of adverse reactions</u><br />Adverse reactions reported in double-blind studies and post marketing experience are listed below as MedDRA preferred term by system organ class and absolute frequency. Frequencies are defined as: very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data). Within each system organ class, adverse reactions are presented in order of decreasing incidence followed by decreasing seriousness.&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:710px"><tbody><tr><td style="vertical-align:top"><p>Adverse reaction</p></td><td colspan="3" style="vertical-align:top; width:355px"><p>Frequency of adverse reactions</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top; width:117px"><p>Pioglitazone</p></td><td style="vertical-align:top; width:118px"><p>Glimepiride</p></td><td style="vertical-align:top; width:119px"><p>Duetact</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Infections and infestations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Upper respiratory tract infection</p></td><td style="vertical-align:top; width:117px"><p>common</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>common</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sinusitis</p></td><td style="vertical-align:top; width:117px"><p>uncommon</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Neoplasms benign, malignant and unspecified (including cysts and polyps)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bladder cancer</p></td><td style="vertical-align:top; width:117px"><p>uncommon</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Blood and lymphatic system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Changes in haematology<sup>1</sup></p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>rare</p></td><td style="vertical-align:top; width:119px"><p>rare</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Immune system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Allergic shock<sup>2</sup></p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Allergic vasculitis<sup>2</sup></p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity and allergic reactions<sup>3</sup></p></td><td style="vertical-align:top; width:117px"><p>not known</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>not known</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Metabolism and nutrition disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia</p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Appetite increased</p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Nervous system disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Hypo-aesthesia</p></td><td style="vertical-align:top; width:117px"><p>common</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top; width:117px"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top; width:117px"><p>uncommon</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Eye disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Visual disturbance<sup>4</sup></p></td><td style="vertical-align:top; width:117px"><p>common</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Macular oedema</p></td><td style="vertical-align:top; width:117px"><p>not known</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>not known</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Ear and labyrinth disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Gastrointestinal disorders<sup>5</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pressure</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Feeling of fullness in the stomach</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Hepatobiliary disorders<sup>6</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Impairment of liver function (with cholestasis and jaundice)</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Sweating</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hypersensitivity to light</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria<sup>2</sup></p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>not known</p></td><td style="vertical-align:top; width:119px"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p>Itching<sup>2</sup></p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>not known</p></td><td style="vertical-align:top; width:119px"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p>Rash<sup>2</sup></p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>not known</p></td><td style="vertical-align:top; width:119px"><p>not known</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Bone fracture<sup>7</sup></p></td><td style="vertical-align:top; width:117px"><p>common</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>common</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Renal and urinary disorders</strong></p></td></tr><tr><td style="vertical-align:top"><p>Glycosuria</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Proteinuria</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>General disorders and administration site conditions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Oedema<sup>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup></p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td colspan="4" style="vertical-align:top; width:709px"><p><strong>Investigations</strong></p></td></tr><tr><td style="vertical-align:top"><p>Weight increased<sup>9</sup></p></td><td style="vertical-align:top; width:117px"><p>common</p></td><td style="vertical-align:top; width:118px"><p>common</p></td><td style="vertical-align:top; width:119px"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Increased lactic dehydrogenase</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Decrease in sodium serum concentrations</p></td><td style="vertical-align:top; width:117px"><p>&nbsp;</p></td><td style="vertical-align:top; width:118px"><p>very rare</p></td><td style="vertical-align:top; width:119px"><p>very rare</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase increase<sup>10</sup></p></td><td style="vertical-align:top; width:117px"><p>not known</p></td><td style="vertical-align:top; width:118px"><p>&nbsp;</p></td><td style="vertical-align:top; width:119px"><p>not known</p></td></tr></tbody></table><p><u>&nbsp;Description of selected adverse reactions</u><br /><sup>1</sup> Moderate to severe thrombocytopenia, leucopenia, erythrocytopenia, granulocytopenia, agranulocytosis, haemolytic anaemia and pancyto-penia may occur. These are in general reversible upon discontinuation of treatment.<br /><sup>2</sup> In very rare cases mild hypersensitivity reactions may develop into serious reactions with dyspnoea, fall in blood pressure and sometimes shock. Hypersensitivity reactions of the skin may occur as itching, rash, and urticaria. Cross allergenicity with sulphonylureas, sulphonamides or related substances is possible.<br /><sup>3</sup> Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. These reactions include anaphylaxis, angioedema, and urticaria.<br /><sup>4</sup> Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic medicinal products.<br /><sup>5</sup> Gastro-intestinal complaints are very rare and seldom lead to discontinuation of therapy.<br /><sup>6</sup> Elevation of liver enzymes may occur. In very rare cases, impairment of liver function (e.g. with cholestasis and jaundice) may develop, as well as hepatitis which may progress to liver failure.<br /><sup>7</sup> A pooled analysis was conducted of adverse event reports of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration. A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%).<br />In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%).<br /><sup>8</sup> Oedema was reported in 6-9% of patients treated with pioglitazone over one year in controlled clinical trials. The oedema rates for comparator groups (sulphonylurea, metformin) were 2-5%. The reports of oedema were generally mild to moderate and usually did not require discontinuation of treatment.<br /><sup>9</sup> In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2 &ndash; 3 kg over one year. This is similar to that seen in a sulphonylurea active comparator group. In combination trials pioglitazone added to a sulphonylurea resulted in a mean weight increase over one year of 2.8 kg.<br /><sup>10</sup> In clinical trials with pioglitazone the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. Mean levels of liver enzymes decreased with treatment with pioglitazone.<br />In controlled clinical trials the incidence of reports of heart failure with pioglitazone treatment was the same as in placebo, metformin and sulphonylurea treatment groups, but was increased when used in combination therapy with insulin. In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo, when added to therapy that included in insulin. However, this did not lead to an increase in mortality in this study. In this study in patients receiving pioglitazone and insulin, a higher percentage of patients with heart failure was observed in patients aged &ge;65 years compared with those less than 65 years (9.7% compared to 4.0%). In patients on insulin with no pioglitazone the incidence of heart failure was 8.2% in those &ge;65 years compared to 4.0% in patients less than 65 years. Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure.</p><p><u>Reporting of suspected adverse reactions</u><br />Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system applied at their country.</p><ul><li>Saudi Arabia:</li></ul><p>The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc</p><ul><li>Other GCC States: Please contact the relevant competent authority.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In clinical studies, patients have taken pioglitazone at higher than the recommended highest dose of 45 mg daily. The maximum reported dose of 120 mg/day for four days, then 180 mg/day for seven days was not associated with any symptoms.</p><p>After ingestion of an overdosage of glimepiride, hypoglycaemia may occur, lasting from 12 to 72 hours, and may recur after initial recovery. Symptoms may not be present for up to 24 hours after ingestion. In general observation in hospital is recommended.</p><p>Nausea, vomiting and epigastric pain may occur. The hypoglycaemia may in general be accompanied by neurological symptoms like restlessness, tremor, visual disturbances, coordination problems, sleepiness, coma and convulsions.</p><p>Treatment of overdosage of Duetact primarily consists of preventing absorption of glimepiride by inducing vomiting and then drinking water or lemonade with activated charcoal (adsorbent) and sodium-sulphate (laxative). If large quantities have been ingested, gastric lavage is indicated, followed by activated charcoal and sodium-sulphate. In case of (severe) overdosage hospitalisation in an intensive care department is indicated. Start the administration of glucose as soon as possible, if necessary by a bolus intravenous injection of 50 ml of a 50% solution, followed by an infusion of a 10% solution with strict monitoring of blood glucose. Further treatment should be symptomatic.</p><p>In particular when treating hypoglycaemia due to accidental intake of Duetact in infants and young children, the dose of glucose given must be carefully controlled to avoid the possibility of producing dangerous hyperglycaemia. Blood glucose should be closely monitored.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, combinations of oral blood glucose lowering drugs; ATC code: A10BD06.</p><p>Duetact combines two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class and glimepiride, a member of the sulphonylurea class. Thiazolidinediones act primarily by reducing insulin resistance and sulphonylureas primarily by inducing insulin release from pancreatic beta cells.</p><p><u>Pioglitazone</u><br />Pioglitazone effects may be mediated by a reduction of insulin resistance. Pioglitazone appears to act via activation of specific nuclear receptors (peroxisome proliferator activated receptor gamma) leading to increased insulin sensitivity of liver, fat and skeletal muscle cells in animals. Treatment with pioglitazone has been shown to reduce hepatic glucose output and to increase peripheral glucose disposal in the case of insulin resistance.&nbsp;</p><p><br />Fasting and postprandial glycaemic control is improved in patients with type 2 diabetes mellitus. The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. A clinical trial of pioglitazone vs. gliclazide as monotherapy was extended to two years in order to assess time to treatment failure (defined as appearance of HbA1c &ge; 8.0% after the first six months of therapy). Kaplan-Meier analysis showed shorter time to treatment failure in patients treated with gliclazide, compared with pioglitazone. At two years, glycaemic control (defined as HbA1c &lt; 8.0%) was sustained in 69% of patients treated with pioglitazone, compared with 50% of patients on gliclazide. In a two-year study of combination therapy comparing pioglitazone with gliclazide when added to metformin, glycaemic control measured as mean change from baseline in HbA1c was similar between treatment groups after one year. The rate of deterioration of HbA1c during the second year was less with pioglitazone than with gliclazide.</p><p>In a placebo controlled trial, patients with inadequate glycaemic control despite a three month insulin optimisation period were randomised to pioglitazone or placebo for 12 months. Patients receiving pioglitazone had a mean reduction in HbA1c of 0.45% compared with those continuing on insulin alone, and a reduction of insulin dose in the pioglitazone treated group.</p><p>HOMA analysis shows that pioglitazone improves beta cell function as well as increasing insulin sensitivity. Two-year clinical studies have shown maintenance of this effect.</p><p>In one year clinical trials, pioglitazone consistently gave a statistically significant reduction in the albumin/creatinine ratio compared to baseline.</p><p>The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week trial in type 2 diabetics. Pioglitazone was associated with significant weight gain. Visceral fat was significantly decreased, while there was an increase in extra-abdominal fat mass. Similar changes in body fat distribution on pioglitazone have been accompanied by an improvement in insulin sensitivity. In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. In clinical trials of up to two years duration, pioglitazone reduced total plasma triglycerides and free fatty acids, and increased HDL-cholesterol levels, compared with placebo, metformin or gliclazide. Pioglitazone did not cause statistically significant increases in LDL-cholesterol levels compared with placebo, whilst reductions were observed with metformin and gliclazide. In a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides. These effects were independent of pioglitazone&rsquo;s effects on glycaemia and were statistically significantly different to glibenclamide.</p><p>In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and pre-existing major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. The study population had an average age of 62 years; the average duration of diabetes was 9.5 years. Approximately one third of patients were receiving insulin in combination with metformin and/or a sulphonylurea. To be eligible patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. Almost half of the patients had a previous myocardial infarction and approximately 20% had had a stroke. Approximately half of the study population had at least two of the cardiovascular history entry criteria. Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, ACE inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates).</p><p>Although the study failed regarding its primary endpoint, which was a composite of all-cause mortality, non-fatal myocardial infarction, stroke, acute coronary syndrome, major leg amputation, coronary revascularisation and leg revascularisation, the results suggest that there are no long-term cardiovascular concerns regarding use of pioglitazone. However, the incidence of oedema, weight gain and heart failure were increased. No increase in mortality from heart failure was observed.</p><p><u>Glimepiride</u><br />Glimepiride acts mainly by stimulating insulin release from pancreatic beta cells.</p><p>As with other sulphonylureas this effect is based on an increase of responsiveness of the pancreatic beta cells to the physiological glucose stimulus. In addition, glimepiride seems to have pronounced extrapancreatic effects also postulated for other sulphonylureas.</p><p><em>Insulin release</em><br />Sulphonylureas regulate insulin secretion by closing the ATP-sensitive potassium channel in the beta cell membrane. Closing the potassium channel induces depolarisation of the beta cell and results &ndash; by opening of calcium channels &ndash; in an increased influx of calcium into the cell. This leads to insulin release through exocytosis. Glimepiride binds with a high exchange rate to a beta cell membrane protein which is associated with the ATP-sensitive potassium channel but which is different from the usual sulphonylurea binding site.<br /><br /><em>Extrapancreatic activity</em><br />The extrapancreatic effects are for example an improvement of the sensitivity of the peripheral tissue for insulin and a decrease of the insulin uptake by the liver.</p><p>The uptake of glucose from blood into peripheral muscle and fat tissues occurs via a special transport proteins, located in the cells membrane. The transport of glucose in these tissues is the rate limiting step in the use of glucose. Glimepiride increases very rapidly the number of active glucose transport molecules in the plasma membranes of muscle and fat cells, resulting in stimulated glucose uptake. Glimepiride increases the activity of the glycosyl-phosphatidylinositol-specific phospholipase C which may be correlated with the induced lipogenesis and glycogenesis in isolated fat and muscle cells.</p><p>Glimepiride inhibits the glucose production in the liver by increasing the intracellular concentration of fructose-2,6-bisphosphate, which in turn inhibits the gluconeogenesis.</p><p><em>General</em><br />In healthy persons, the minimum effective oral dose is approximately 0.6 mg. The effect of glimepiride is dose-dependent and reproducible. The physiological response to acute physical exercise, reduction of insulin secretion, is still present under glimepiride.<br />There was no significant difference in effect regardless of whether glimepiride was given 30 minutes or immediately before a meal. In diabetic patients, good metabolic control over 24 hours can be achieved with a single daily dose.</p><p>Although the hydroxy metabolite of glimepiride caused a small but significant decrease in serum glucose in healthy persons, it accounts for only a minor part of the total effect.</p><p><u>Paediatric population</u><br />The European Medicines Agency has waived the obligation to submit the results of studies with Duetact in all subsets of the paediatric population in Type 2 Diabetes Mellitus. See section 4.2 for information on paediatric use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Duetact</u><br />Studies in human volunteers have shown Duetact to be bioequivalent to the administration of pioglitazone and glimepiride given as separate tablets.</p><p>The following statements reflect the pharmacokinetic properties of the individual active substances of Duetact.</p><p>Pioglitazone<br /><em>Absorption</em><br />Following oral administration, pioglitazone is rapidly absorbed, and peak plasma concentrations of unchanged pioglitazone are usually achieved 2 hours after administration. Proportional increases of the plasma concentration were observed for&nbsp; doses from 2-60 mg. Steady state is achieved after 4-7 days of dosing. Repeated dosing does not result in accumulation of the compound or metabolites. Absorption is not influenced by food intake. Absolute bioavailability is greater than 80%.</p><p><em>Distribution</em><br />The estimated volume of distribution in humans is 0.25 L/kg.</p><p>Pioglitazone and all active metabolites are extensively bound to plasma protein (&gt; 99%).</p><p><em>Biotransformation</em><br />Pioglitazone undergoes extensive hepatic metabolism by hydroxylation of aliphatic methylene groups. This is predominantly via cytochrome P450 2C8 although other isoforms may be involved to a lesser degree. Three of the six identified metabolites are active (M-II, M-III, and M-IV). When activity, concentrations and protein binding are taken into account, pioglitazone and metabolite M-III contribute equally to efficacy. On this basis M-IV contribution to efficacy is approximately three-fold that of pioglitazone, whilst the relative efficacy of M-II is minimal.</p><p><em>In vitro</em> studies have shown no evidence that pioglitazone inhibits any subtype of cytochrome P450. There is no induction of the main inducible P450 isoenzymes 1A, 2C8/9, and 3A4 in man.</p><p>Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon and metformin. Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5).</p><p><em>Elimination</em><br />Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). In animals, only a small amount of unchanged pioglitazone can be detected in either urine or faeces. The mean plasma elimination half-life of unchanged pioglitazone in man is 5 to 6 hours and for its total active metabolites 16 to 23 hours.</p><p><em>Linearity/non-linearity</em><br />Single dose studies demonstrate linearity of pharmacokinetics in the therapeutic dose range.</p><p><em>Elderly</em><br />Steady state pharmacokinetics are similar in patients age 65 and over and young subjects.</p><p><em>Patients with renal impairment</em><br />In patients with renal impairment, plasma concentrations of pioglitazone and its metabolites are lower than those seen in subjects with normal renal function, but oral clearance of parent substance is similar. Thus free (unbound) pioglitazone concentration is unchanged.</p><p><em>Patients with hepatic impairment</em><br />Total plasma concentration of pioglitazone is unchanged, but with an increased volume of distribution. Intrinsic clearance is therefore reduced, coupled with a higher unbound fraction of pioglitazone.</p><p><u>Glimepiride</u><br /><em>Absorption</em><br />The bioavailability of glimepiride after oral administration is complete. Food intake has no relevant influence on absorption, only absorption rate is slightly diminished. Maximum serum concentrations (C<sub>max</sub>) are reached approximately 2.5 hours after oral intake (mean 0.3 &mu;g/ml during multiple dosing of 4 mg daily).</p><p><em>Distribution</em><br />Glimepiride has a very low distribution volume (approximately 8.8 litres) which is roughly equal to the albumin distribution space, high protein binding (&gt; 99%), and a low clearance (approximately 48 ml/min).</p><p>In animals, glimepiride is excreted in milk. Glimepiride is transferred to the placenta. Passage of the blood brain barrier is low.</p><p><em>Biotransformation and elimination</em><br />Mean dominant serum half-life, which is of relevance for the serum concentrations under multiple-dose conditions, is about 5 to 8 hours. After high doses, slightly longer half-lives were noted.</p><p>After a single dose of radiolabelled glimepiride, 58% of the radioactivity was recovered in the urine, and 35% in the faeces. No unchanged substance was detected in the urine. Two metabolites &ndash; most probably resulting from hepatic metabolism (major enzyme is CYP2C9) &ndash; were identified both in urine and faeces: the hydroxy derivative and the carboxy derivative. After oral administration of glimepiride, the terminal half-lives of those metabolites were 3 to 6 and 5 to 6 hours respectively.</p><p>Comparison of single and multiple once-daily dosing revealed no significant differences in pharmacokinetics, and the intra-individual variability was very low. There was no relevant accumulation.</p><p>Pharmacokinetics were similar in males and females, as well as in young and elderly (above 65 years) patients. In patients with low creatinine clearance, there was a tendency for glimepiride clearance to increase and for average serum concentrations to decrease, most probably resulting from a more rapid elimination because of lower protein binding. Renal elimination of the two metabolites was impaired.</p><p>Overall no additional risk of accumulation is to be assumed in such patients.</p><p>Pharmacokinetics in five non-diabetic patients after bile duct surgery were similar to those in healthy persons.</p><p><em>Linearity/non-linearity</em><br />There is a linear relationship between dose and both C<sub>max</sub> and AUC (area under the time/concentration curve).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No animal studies have been conducted with the combined products of Duetact. The following data are findings in studies performed with pioglitazone or glimepiride individually.</p><p><u>Pioglitazone</u><br />In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. In addition, increased fatty deposition and infiltration were observed. These findings were observed across species at plasma concentrations &le; 4 times the clinical exposure. Foetal growth restriction was apparent in animal studies with pioglitazone. This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.</p><p>Pioglitazone was devoid of genotoxic potential in a comprehensive battery of <em>in vivo</em> and <em>in vitro</em> genotoxicity assays. An increased incidence of hyperplasia (males and females) and tumours (males) of the urinary bladder epithelium was apparent in rats treated with pioglitazone for up to 2 years.</p><p>The formation and presence of urinary calculi with subsequent irritation and hyperplasia was postulated as the mechanistic basis for the observed tumourigenic response in the male rat. A 24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder. Dietary acidification significantly decreased but did not abolish the incidence of tumours. The presence of microcrystals exacerbated the hyperplastic response but was not considered to be the primary cause of hyperplastic changes. The relevance to humans of the tumourigenic findings in the male rat cannot be excluded.</p><p>There was no tumourigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months.<br /><br />In an animal model of familial adenomatous polyposis (FAP), treatment with two other thiazolidinediones increased tumour multiplicity in the colon. The relevance of this finding is unknown.</p><p><u>Glimepiride</u><br />Preclinical effects observed occurred at exposures sufficiently in excess of the maximum human exposure as to indicate little relevance to clinical use, or were due to the pharmacodynamic action (hypoglycaemia) of the compound. This finding is based on conventional safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenicity, and reproduction toxicity studies. In the latter (covering embryotoxicity, teratogenicity and developmental toxicity), undesirable effects observed were considered to be secondary to the hypoglycaemic effects induced by the compound in dams and in offspring.</p><p><u>Environmental Risk Assessment (ERA)</u><br />No environmental impact is anticipated from the clinical use of pioglitazone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Hydroxpropylcellulose</li><li>Croscarmellose sodium</li><li>Lactose monohydrate</li><li>Magnesium stearate</li><li>Polysorbate 80</li><li>Cellulose, microcrystalline.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>HDPE White jar, 33 MM CRC with cap.</p><p>Pack size: 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jazeera Pharmaceutical Industries (JPI)
Riyadh, Saudi Arabia
11666 Riyadh, P.O.Box 106229
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11 July 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>